Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 4036.46% ano a ano.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 49.80M.
Subavaliada
O PE mais recente da empresa é -32.49, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 301.10M ações, um aumento de 2.34% em relação ao trimestre anterior.
Mantido por ETHSX
O Super Investidor ETHSX possui 884.79 ações desta empresa.